N-terminal glycation of cholecystokinin-8 abolishes its insulinotropic action on clonal pancreatic B-cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1452, Issue 1, 1999, Pages 60-67

  Abdel Wahab, Yasser H A ^a   O'Harte, Finbarr P M ^a   Mooney, Mark H ^a   Conlon, J Michael ^b   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRIN BD11 cell; Cholecystokinin 8; Glycation; Insulin secretion

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; INSULIN;

AMINO TERMINAL SEQUENCE; ARTICLE; GLYCATION; HUMAN; HUMAN CELL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLYCOSYLATION; HUMANS; INSULIN; ISLETS OF LANGERHANS; SINCALIDE; SORBITOL;

EID: 0032881940     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(99)00108-1     Document Type: Article

References (43)

1. R.A. Liddle, Cholecystokinin, in: J.H. Walsh, G.J. Dockray (Eds.), Gut Peptides Biochemistry and Physiology, Raven Press, New York, 1994, pp. 175-216.
2. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides. 15:1995;731-755.
3. Cantor P. Cholecystokinin in plasma. Digestion. 42:1989;181-201.
4. Hoffmann P., Eberlein G.A., Reeve J.R. Jr., Bunte R.H., Grandt D., Goebell H., Eysselein V.E. Comparison of clearance and metabolism of infused cholecystokinin-8 and 58 in dog. Gastroenterology. 105:1993;1732-1736.
5. Liddle R.A., Goldfine I.D., Rosen M.S., Taplitz R.A., Williams J.A. Cholecystokinin bioactivity in human plasma: molecular forms, responses to feeding and relationship to gall bladder contraction. J. Clin. Invest. 75:1985;1144-1152.
6. Verspohl E.J., Ammon H.P.T., Williams J.A., Goldfine I.D. Evidence that cholecystokinin interacts with specific receptors and regulates insulin release in isolated rat islets of Langerhans. Diabetes. 35:1986;38-43.
7. Zawalich W.S., Cote S.B., Diaz V.A. Influence of cholecystokinin on insulin output from isolated perifused pancreatic islets. Endocrinology. 119:1986;616-621.
8. S. Karlsson, T. Fridolf, B. Ahren, Islet mechanisms of CCK-8 and GLP-1(7-36)amide, in: P.R. Flatt, S. Lenzen (Eds.), Frontiers of Insulin Secretion and Pancreatic B-Cell Research, Smith-Gordon, London, 1994, pp. 337-342.
9. 2 contributes to the insulinotropic action of cholecystokinin-8 in rat islets: Dissociation from the mechanism of carbachol. Diabetes. 47:1998;1436-1443.
10. J.C. Brown, Enteroinsular axis, in: J.H. Walsh, G.J. Dockray (Eds.), Gut Peptides Biochemistry and Physiology, Raven Press, New York, 1994, pp. 765-784.
11. P.R. Flatt, Hormonal and neural control of endocrine pancreatic function, in: J. Pickup, G. Williams (Eds.), Textbook of Diabetes, 2 edn., Blackwell Scientific Publications, Oxford, 1997, pp. 9.1-9.17.
12. Abdel-Wahab Y.H.A., O'Harte F.P.M., Boyd A.C., Barnett C.R., Flatt P.R. Glycation of insulin results in reduced biological activity in mice. Acta Diabetol. 34:1997;265-270.
13. O'Harte F.P.M., Gray A.M., Abdel-Wahab Y.H.A., Flatt P.R. Effects of non-glycated and glycated glucagon-like peptide-1 amide on glucose metabolism in isolated mouse abdominal muscle. Peptides. 18:1997;1327-1333.
14. O'Harte F.P.M., Abdel-Wahab Y.H.A., Conlon J.M., Flatt P.R. Glycation of glucagon-like peptide-1 (7-36) amide: Characterisation and impaired action on rat insulin secreting cells. Diabetologia. 41:1998;1187-1193.
15. O'Harte F.P.M., Mooney M.H., Kelly C.M.N., Flatt P.R. Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes. 47:1998;1619-1624.
16. O'Harte F.P.M., Abdel-Wahab Y.H.A., Conlon J.M., Flatt P.R. Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochim. Biophys. Acta. 1425:1998;319-327.
17. O'Harte F.P.M., Mooney M., Flatt P.R. N-terminally glycated gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes. 48:1999;758-765.
18. Morley J.E. Neuropeptide regulation of appetite and weight. Endocrinol. Rev. 8:1987;256-287.
19. Silver A.J., Morley J.E. Role of CCK in the regulation of food intake. Prog. Neurobiol. 36:1991;23-34.
20. Rushakoff R.A., Goldfine I.D., Beccaria L.J., Mathur A., Brand R.J., Liddle R.A. Reduced postprandial cholecystokinin (CCK) secretion in patients with non-insulin-dependent diabetes mellitus: Evidence for a role of CCK in regulating postprandial hyperglycemia. J. Clin. Endocrinol. Metab. 76:1993;489-493.
21. McClenaghan N.H., Barnett C.R., Ah-Sing E., Abdel-Wahab Y.H.A., O'Harte F.P.M, Yoon T.W., Swanton-Flatt S.K., Flatt P.R. Characterisation of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes. 45:1996;1132-1140.
22. Flatt P.R., Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia. 20:1981;573-577.
23. O'Harte F.P.M., Højrup P., Barnett C.R., Flatt P.R. Identification of the site of glycation of human insulin. Peptides. 17:1996;1323-1330.
24. Abdel-Wahab Y.H.A., O'Harte F.P.M., Ratcliff H., McClenaghan N.H., Barnett C.R., Flatt P.R. Glycation of insulin in the islets of Langerhans of normal and diabetic animals. Diabetes. 45:1996;1489-1496.
25. Abdel-Wahab Y.H.A., O'Harte F.P.M., Barnett C.R., Flatt P.R. Characterisation of insulin glycation in insulin-secreting cells maintained in tissue culture. J. Endocrinol. 152:1997;59-67.
26. McClenaghan N.H., Barnett C.R., O'Harte F.P.M., Flatt P.R. Mechanisms of amino acid induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B-cell line. J. Endocrinol. 151:1996;349-357.
27. McClenaghan N.H., Flatt P.R., Bailey C.J. Insulin-releasing action of the novel antidiabetic agent BTS 67582. Br. J. Pharmacol. 123:1998;400-404.
28. Verspohl E.J., Hafner B., He X., Knittle J.J. Evidence for cholecystokinin receptor subtype in endocrine pancreas. Peptides. 15:1994;1353-1360.
29. Sakamoto C., Goldfine I.D., Roach E., Williams J.A. Localisation of saturable CCK binding sites in rat pancreatic islets by light and electron microscope autoradiography. Diabetes. 34:1985;390-394.
30. Zawalich W.S., Takuwa N., Takuwa Y., Diaz V.A., Rasmussen H. Interactions of cholecystokinin and glucose in rat pancreatic islets. Diabetes. 36:1987;426-433.
31. Karlsson S., Ahren B. Cholecystokinin-stimulated insulin secretion and protein kinase C in rat pancreatic islets. Acta Physiol. Scand. 142:1991;397-403.
32. Fridolf T., Karlsson S., Ahren B. Effects of CCK-8 on the cytoplasmic free calcium concentration in isolated rat islet cells. Biochem. Biophys. Res. Commun. 184:1992;878-882.
33. P.-O. Berggren, P. Rorsman, S. Efendic, C.-G. Ostenson, P.R. Flatt, T. Nilsson, P. Arkhammar, L. Juntti-Berggren, Mechanisms of action of enteroinsular hormones, islet peptides and neural input of the insulin secretory process, in: P.R. Flatt (Ed.), Nutrient Regulation of Insulin Secretion, Portland Press, London, 1992, pp. 289-318.
34. Komatsu R., Matsuyama T., Namba M. Glucagonostatic and insulinotropic action of glucagon-like peptide-1-(7-36)-amide. Diabetes. 38:1989;902-905.
35. Weir G.C., Mojsov S., Hendrick G.K., Habener J.F. Glucagon-like peptide-1(7-37) actions on endocrine pancreas. Diabetes. 38:1989;338-342.
36. Wank S.A., Pisegna J.R., Weerth A. Cholecystokinin receptor family: Molecular cloning, structure and functional expression in rat, guinea pig and human. Ann. NY Acad. Sci. 713:1994;49-66.
37. Wank S.A. Cholecystokinin receptors. Am. J. Physiol. 269:1995;G628-G646.
38. Sandberg E., Ahren B., Tendler D., Efendic S. Cholecystokinin CCK-33 stimulates insulin secretion from the perfused rat pancreas: Studies on the structure-activity relationship. Pharmacol. Toxicol. 63:1988;42-45.
39. Gefel D., Hendrick G.K., Mojsov S., Habener J., Weir G.C. Glucagon-like peptide-1 analogs: effects on insulin secretion and 3′,5′-monophosphate formation. Endocrinology. 126:1990;2164-2168.
40. Göke R., Fehmann H.-C., Linn T., Schmidt H., Karuse M., Eng J., Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting B-cells. J. Biol. Chem. 268:1993;19650-19655.
41. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous peptide in vivo. J. Clin. Endocrinol. Metab. 80:1995;952-957.
42. Deacon C.F., Knudsen L.B., Madsen K., Wiberg F.C., Jacobsen O., Holst J.J. Dipepidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia. 41:1998;271-278.
43. Grandt D., Sieburg B., Schimiczek M., Becker U., Holtmann G., Layer P., Reeve J.R., Eysselein V.E., Goebell H., Mueller M. Is GLP-1(9-36) amide an endogenous antagonist at GLP-1 receptors? Digestion. 55:1994;302.